TABLE 3

Key pharmacokinetic parameters of ARBs

Data were obtained from the regulatory authority approved U.S. prescribing information except for azilsartan where the corresponding Japanese document was used. For valsartan information from the prescribing information for both the capsule and tablet formulation were used.

	t_max	Oral Bioavailability	V_d	Plasma Protein Binding	t_1/2	Total Clearance	Renal Clearance
	h	%	liters	%	h
Azilsartan	1.8–2.4	75	21	>99	13	130–145 ml/min	2.2–2.4 ml/min
Azilsartan medoxomil	1.5–3	60	16	99.5	11	n.r.	2.3 ml/min
Candesartan cilexetil	3–4	15	0.13 l/kg	>99	9	0.37 ml/min/kg	0.19 ml/min/kg
Eprosartan	1–2	13	308^{^d}	98	20	800^{^d} ml/min	n.r.
Irbesartan	1.5–2	60–80	53–93	90	11–15	157–176 ml/min	3.0–3.5 ml/min
Losartan	1 and 3–4^{^a}	33	34 and 12^{^a}	98.7 and 99.8^{^a}	2 and 6–9^{^a}	600 ml/min and 50 ml/min	75 ml/min and 25 ml/min
Olmesartan medoxomil	1–2	26	17	99	13	21.7 ml/min	10 ml/min
Telmisartan	0.5–1	42–58^{^b}	500	>99.5	24	>800 ml/min	n.a.
Valsartan^c	2–4	25	17	95	6	33.3 ml/min	10.3 ml/min

n.r., not reported; n.a., not applicable.
↵^a Values for parent compound and active metabolite EXP3174, respectively.
↵^b Values for 40 and 160 mg, respectively (dose-dependent bioavailability).
↵^c Values apply similarly to the tablet and capsule formulations.
↵^d Values derived from population pharmacokinetic analysis, a study in healthy volunteers reported values of 12.6 liters and 132 ml/min, respectively (Tenero et al., 1998b).